about
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesFirst line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule.Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis.Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers.First- and second-line therapy for advanced nonsmall cell lung cancer.Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy.Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.[Clinical research activity of the French cancer cooperative network: Overview and perspectives].Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report.Personalized chemotherapy of lung cancer: What the radiologist should know.Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR).Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.Primary lung adenocarcinoma: characteristics by smoking habit and sex.Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma.Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: influence of ATS/ERS/IASLC guidelines.High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.CT characteristics of resolving ground-glass opacities in a lung cancer screening programme.Professional practice and accessibility to equipment in thoracic oncology. Results of a survey in Rhônes-Alpes region (France).[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study].Use of intensive care in patients with nonresectable lung cancer.Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study.
P50
Q27852316-AFED28E2-B919-447E-B439-10244EA0A14EQ27853282-1E28B18E-C6A0-4E48-8F97-32C04A839419Q28289431-58127581-51A0-4055-AF65-520592C6DB46Q33365023-A4F853CF-90D7-48A0-8313-B06AE5ACFF66Q34727911-9C99DF35-AF19-4F24-ADFA-AE3DEBC76221Q36757298-89C353CD-2B5F-4C2D-BA71-30562622EE9BQ37428358-280ABEA9-D613-4A18-B4D2-683A7F55C9BDQ37965391-B9C4A1E1-0FDD-4589-94E2-2513674A4E4EQ38313390-8ED9D576-A506-455F-A52B-E496B2256EEAQ38369864-AC160968-3592-4CAA-A8B0-D4726F5CEC9FQ38384492-A763A41C-0909-4A8F-9B64-2AB547715922Q38463203-04DA42DE-C83F-4E2B-9014-59D0F42EDDA6Q38629823-4A4969BC-B0F5-497B-BE26-D2D74AEC8E8DQ38645064-5CED1465-BC4F-49A9-B0A5-0E6CD6737AF3Q38692485-BD1FDB02-F501-470B-A67B-94E62531B75EQ38726834-24E92C32-E954-48A1-A657-8875E5478647Q38887417-9CAB7181-C430-4F93-8361-21E53903BE4FQ39105350-976CA368-5F36-4854-B572-C462BB1B53D4Q39590838-4CE75A68-540A-4067-909F-345E12FE046AQ40081862-3F8991C1-DB24-4449-AD54-FDED346F0603Q40195574-9CB5802E-688A-4F8B-94BE-E088E51F7FE6Q40196022-89865E93-9FF2-41A5-938D-301DA39EC7EBQ40258294-BF56DE84-6997-400A-B1BE-41EEDFFAC6D3Q41008161-A700C3D4-10D6-49C9-8CED-94F92BD6A51CQ41275901-56F2F078-3998-493C-92D0-7C1B8EBF3A9BQ41356383-53A9FA4F-81CB-400D-8A58-18EC4C3E2DD4Q41538585-6682394D-BE87-4440-9C1F-EEC9D2281468Q41683156-E442CE24-56EB-4EC0-9231-D17920575841Q41714739-DEB6ADBA-8712-43AF-A9F7-D835364939E3Q43807392-D9068A20-1F5E-4A54-8E65-4306A8B807EEQ44101800-10263781-D654-4CAA-AEE4-2633876B5C0BQ45194272-D38EAECD-A26D-4DD4-B332-A00FD54FAA07Q45895901-2D842A9E-3F9C-4BC9-91C0-C78EB027392FQ45896924-9A1CF4AB-125B-4645-A1A4-D1AC9139BFB3Q46110772-8057FB21-EC6F-4C49-84F2-B3CB3361AA2EQ46526278-918C74A3-0872-46F0-A231-45038797DB5EQ46743460-9976D1B1-9D5F-42F3-9DE9-72FF59EA99D3Q46792474-E8EB354E-6DA8-4139-83F7-36E2BA36DA1AQ47236718-4277C790-38C8-474B-9119-6A8D6485C4BEQ47623760-1E55D92A-72BC-43BB-87D2-2FF3E5D67A2C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Denis Moro-Sibilot
@ast
Denis Moro-Sibilot
@en
Denis Moro-Sibilot
@es
Denis Moro-Sibilot
@nl
type
label
Denis Moro-Sibilot
@ast
Denis Moro-Sibilot
@en
Denis Moro-Sibilot
@es
Denis Moro-Sibilot
@nl
prefLabel
Denis Moro-Sibilot
@ast
Denis Moro-Sibilot
@en
Denis Moro-Sibilot
@es
Denis Moro-Sibilot
@nl
P106
P31
P496
0000-0001-6776-8610